Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients
NCT ID: NCT03011749
Last Updated: 2019-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
6 participants
INTERVENTIONAL
2017-01-31
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
NCT01717391
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
NCT00775268
FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia
NCT02392429
Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy
NCT02139150
FLT PET Imaging for Cervical Cancer
NCT01075412
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FLT PET/CT
FLT PET/CT
FLT PET/CT
FLT PET/CT before first series of Radium-223 and after 2 series
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FLT PET/CT
FLT PET/CT before first series of Radium-223 and after 2 series
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Eligible for Radium-223 therapy
* Informed consent
Exclusion Criteria
* Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marie Øbro Fosbøl
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H1603551
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.